Commercially Insured Patients Can Receive UP TO 12 MONTHS of BEVESPI AEROSPHERE for FREE*

BEVESPI Coupon Savings Card BEVESPI Coupon Savings Card
All eligible commercially insured patients will pay as little as $0* with the BEVESPI AEROSPHERE Guarantee Program.
Help reduce your patients’ prescription costs. Share the BEVESPI AEROSPHERE Guarantee Program with your patients.*

*Restrictions apply. See full eligibility information below.

*Restrictions apply. See full eligibility information below.



Patients may be eligible for this offer if they are insured by commercial insurance and their insurance does not cover the full cost of their prescription, or they are not insured and are responsible for the cost of their prescriptions.

Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.

Patients enrolled in a state or federally funded prescription insurance program may not use this savings card even if they elect to be processed as an uninsured (cash-paying) patient.

This offer is not insurance, is restricted to residents of the United States and Puerto Rico, and to patients over 18 years of age. If the patient uses a mail-order pharmacy, please contact the pharmacy provider to confirm if this offer will be accepted.


Eligible commercially insured patients with a valid prescription for BEVESPI AEROSPHERE® (glycopyrrolate/formoterol fumarate) who present this savings card at participating pharmacies will receive 100% off their out-of-pocket costs for each 30-day supply (1 inhaler). Patients who pay cash for their prescription will receive up to $100 in savings on their out-of-pocket costs for each prescription. This offer is good for 12 uses and each inhaler counts as 1 use. Patient is responsible for applicable taxes, if any. Card expires on 12/31/18. For questions regarding this offer, please call 1-877-469-1844.

Non-transferable, limited to one per person, cannot be combined with any other offer. Void where prohibited by law, taxed or restricted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer.

AstraZeneca reserves the right to rescind, revoke, or amend this offer, eligibility and terms of use at any time without notice. This offer is not conditioned on any past, present or future purchase, including refills. Offer must be presented along with a valid prescription for BEVESPI AEROSPHERE® (glycopyrrolate/formoterol fumarate) at the time of purchase.

If a patient’s commercial insurance plan does not cover BEVESPI AEROSPHERE® (glycopyrrolate/formoterol fumarate), use of this offer permits his/her healthcare provider or pharmacy to share limited information with certain AstraZeneca vendors to determine if additional resources may be available; and to act on his/her behalf to initiate any processes that may be necessary to access these resources.


Program managed by PSKW, LLC, on behalf of AstraZeneca.






WARNING: Long-acting beta2-adrenergic agonists (LABAs), such as formoterol fumarate, one of the active ingredients in BEVESPI AEROSPHERE, increase the risk of asthma-related death. A placebo-controlled trial with another LABA (salmeterol) showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABAs, including formoterol fumarate.

The safety and efficacy of BEVESPI AEROSPHERE in patients with asthma have not been established. BEVESPI AEROSPHERE is not indicated for the treatment of asthma.


All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication. BEVESPI is contraindicated in patients with hypersensitivity to glycopyrrolate, formoterol fumarate, or to any component of the product.


  • BEVESPI should not be initiated in patients with acutely deteriorating chronic obstructive pulmonary disease (COPD), which may be a life-threatening condition

  • BEVESPI should not be used for the relief of acute symptoms (ie, as rescue therapy for the treatment of acute episodes of bronchospasm). Acute symptoms should be treated with an inhaled short-acting beta2-agonist

  • BEVESPI should not be used more often or at higher doses than recommended, or with other LABAs, as an overdose may result

  • If paradoxical bronchospasm occurs, discontinue BEVESPI immediately and institute alternative therapy

  • If immediate hypersensitivity reactions occur, in particular, angioedema, urticaria, or skin rash, discontinue BEVESPI at once and consider alternative treatment

  • BEVESPI can produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, blood pressure, or symptoms. If such effects occur, BEVESPI may need to be discontinued

  • Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines

  • Be alert to hypokalemia and hyperglycemia

  • Worsening of narrow-angle glaucoma or urinary retention may occur. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction, and instruct patients to contact a physician immediately if symptoms occur


The most common adverse reactions with BEVESPI (≥2% and more common than placebo) were: cough, 4.0% (2.7%), and urinary tract infection, 2.6% (2.3%).


  • Use caution if administering additional adrenergic drugs because the sympathetic effects of formoterol may be potentiated

  • Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of formoterol

  • Use with caution in patients taking non–potassium-sparing diuretics, as the ECG changes and/or hypokalemia may worsen with concomitant beta2-agonists

  • The action of adrenergic agonists on the cardiovascular system may be potentiated by monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs known to prolong the QTc interval. Therefore, BEVESPI should be used with extreme caution in patients being treated with these agents

  • Use beta-blockers with caution as they not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in patients with COPD

  • Avoid co-administration of BEVESPI with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects


BEVESPI AEROSPHERE is a combination of glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.


Not indicated for the relief of acute bronchospasm or for the treatment of asthma.

Please read full Prescribing Information, including Boxed WARNING, and Medication Guide and Instructions for Use for BEVESPI AEROSPHERE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.